Last reviewed · How we verify
GDC-0994
At a glance
| Generic name | GDC-0994 |
|---|---|
| Sponsor | Genentech, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- DIARRHOEA
- NAUSEA
- VOMITING
- DYSPNOEA
- DERMATITIS ACNEIFORM
- RASH
- ANAEMIA
- THROMBOCYTOPENIA
- ACUTE MYOCARDIAL INFARCTION
- LEFT VENTRICULAR DYSFUNCTION
- SINUS BRADYCARDIA
- SINUS TACHYCARDIA
Key clinical trials
- A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors (PHASE1)
- A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |